NCT05433610

Non-invasive Ventilation in Patients With Cardiac Heart Failure

Completed NA Last updated 15 December 2022

What this trial tests

NA trial testing Non-invasive Ventilation in Heart Failure in 12 participants. Completed in 5 December 2022.

Timeline

28 June 2022

Primary endpoint
5 December 2022

5 December 2022

Quick facts

Lead sponsor	University of Gran Rosario
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	28 June 2022
Primary completion	5 December 2022
Estimated completion	5 December 2022
Sites	1 location across Argentina

Drugs / interventions tested

• Non-invasive Ventilation

Conditions studied

• Heart Failure — all drugs for Heart Failure →

Sponsor

University of Gran Rosario

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with heart failure (HF) have a reduced exercise tolerance as the main result of the disease. This exercise intolerance is due to heart conditions, but also to dysfunction of the respiratory and peripheral muscles. Various factors such as chronic hypoxia, oxidative stress, nutritional depletion, peripheral muscle disuse, effects of medications, and sympathetic-vagal imbalance are major contributors to deconditioning. In this scenario, the use of non-invasive ventilatory support (NIV) arises as an adjunct to cardiac rehabilitation in the attempt to improve the functional capacity of patients, since NIV reduces work of breathing, improves oxygenation and increases lung compliance associated with improved ejection volume, due to increased intrathoracic pressure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Is non-invasive ventilation effective in improving the exercise capacity in patients with cardiac heart failure?: A randomised crossover trial.
   Mazzucco G, Torres-Castro R, Intelangelo L, Lista-Paz A, et al · · 2025 · PMID 40622949 · DOI 10.1371/journal.pone.0327399